(Circulation. 1999;99:2396-2401.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Division of Cardiology, University Hospitals Zurich and Bern, Switzerland.
Correspondence to Otto M. Hess, MD, Professor of Cardiology, Swiss Heart Center, University Hospital, CH-3010 Bern, Switzerland. E-mail otto.martin.hess{at}insel.ch
BackgroundPrevious experimental studies have shown that nitric oxide (NO) modulates cardiac function by an abbreviation of systolic contraction and an enhancement of diastolic relaxation. However, the response to NO donors of patients with severe pressure-overload hypertrophy and diastolic dysfunction is unknown.
Methods and ResultsIntracoronary NO donors were
given to 17 patients with severe aortic stenosis. A
dose-response curve was obtained with nitroglycerin
(30, 90, and 150 µg) in 11 patients and sodium nitroprusside (1, 2,
and 4 µg/min) in 6. Left ventricular (LV) high-fidelity
pressure measurements with simultaneous LV angiograms were
performed at baseline and after the maximal dose of NO. The
dose-response curve for intracoronary NO donors showed a marked
fall in LV end-diastolic pressure, from 23 to 14
mm Hg (-39%; P<0.0001), whereas LV peak
systolic pressure fell only slightly, from 206 to 196
mm Hg (-4%; P<0.01). End-diastolic
chamber stiffness decreased from 0.12 to 0.07 mm Hg/mL
(P<0.0001) and end-systolic stiffness from 1.6
to 1.3 mm Hg/mL (P<0.01). Heart rate, right
atrial pressure, LV ejection fraction, the time constant of isovolumic
pressure decay (
), and LV filling rates remained unchanged.
ConclusionsIn patients with severe pressure-overload hypertrophy, intracoronary NO donors exert a marked decrease in LV end-diastolic pressure without affecting LV systolic pump function. Thus, the hypertrophied myocardium appears to be particularly susceptible to NO donors, with a marked improvement in diastolic function.
Key Words: nitric oxide nitroglycerin sodium nitroprusside hypertrophy diastole
This article has been cited by other articles:
![]() |
G. Ruiz-Hurtado, M. Fernandez-Velasco, M. Mourelle, and C. Delgado LA419, a Novel Nitric Oxide Donor, Prevents Pathological Cardiac Remodeling in Pressure-Overloaded Rats Via Endothelial Nitric Oxide Synthase Pathway Regulation Hypertension, December 1, 2007; 50(6): 1049 - 1056. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Seddon, A. M. Shah, and B. Casadei Cardiomyocytes as effectors of nitric oxide signalling Cardiovasc Res, July 15, 2007; 75(2): 315 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. B. Popovic, U. N. Khot, G. M. Novaro, F. Casas, N. L. Greenberg, M. J. Garcia, G. S. Francis, and J. D. Thomas Effects of sodium nitroprusside in aortic stenosis associated with severe heart failure: pressure-volume loop analysis using a numerical model Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H416 - H423. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Paulus and J. G. F. Bronzwaer Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H8 - H13. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Scorsin, A. Mebazaa, N. A. Attar, B. Medini, J. Callebert, R. Raffoul, R. Ramadan, J. M. Maillet, A. Ruffenach, F. Simoneau, et al. Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1022 - 1029. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. F. Bronzwaer, C. Heymes, C. A. Visser, and W. J. Paulus Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H10 - H16. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mak, E. R. Azevedo, P. P. Liu, and G. E. Newton Effect of Hyperoxia on Left Ventricular Function and Filling Pressures in Patients With and Without Congestive Heart Failure Chest, August 1, 2001; 120(2): 467 - 473. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M Bryant, C. E Sears, L. Rigg, D. A Terrar, and B. Casadei Nitric oxide does not modulate the hyperpolarization-activated current, If, in ventricular myocytes from spontaneously hypertensive rats Cardiovasc Res, July 1, 2001; 51(1): 51 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Grossman Defining Diastolic Dysfunction Circulation, May 2, 2000; 101(17): 2020 - 2021. [Full Text] [PDF] |
||||
![]() |
L. Mandinov, F. R. Eberli, C. Seiler, and O. M. Hess Diastolic heart failure Cardiovasc Res, March 1, 2000; 45(4): 813 - 825. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |